Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Aclaris Therapeutics, Inc. | acrs-20191231ex321b503ff.htm |
| EX-31.2 - EX-31.2 - Aclaris Therapeutics, Inc. | acrs-20191231ex312c0ce79.htm |
| EX-31.1 - EX-31.1 - Aclaris Therapeutics, Inc. | acrs-20191231ex3119e3c71.htm |
| EX-21.1 - EX-21.1 - Aclaris Therapeutics, Inc. | acrs-20191231ex2114a983e.htm |
| EX-10.20 - EX-10.20 - Aclaris Therapeutics, Inc. | acrs-20191231ex10208578b.htm |
| EX-10.15 - EX-10.15 - Aclaris Therapeutics, Inc. | acrs-20191231ex10157228e.htm |
| EX-10.14 - EX-10.14 - Aclaris Therapeutics, Inc. | acrs-20191231ex101456d79.htm |
| EX-4.2 - EX-4.2 - Aclaris Therapeutics, Inc. | acrs-20191231ex42f1240e5.htm |
| 10-K - 10-K - Aclaris Therapeutics, Inc. | acrs-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-212095) and Form S-8 (Nos. 333-230614, 333-223922, 333-220149, 333-216703, 333-210379, and 333-207434) of Aclaris Therapeutics, Inc. of our report dated February 25, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 25, 2020